PYFA Subsidiary, Holi Pharma, Once Again Secures Marketing Authorization Extensions from BPOM RI

Jakarta, December 22, 2025 — PT Holi Pharma, a subsidiary of PYFA, has once again demonstrated its commitment to maintaining quality standards and regulatory compliance within the national pharmaceutical industry. This is marked by the receipt of Marketing Authorization (NIE) renewals from the Indonesian Food and Drug Authority (BPOM). This achievement serves as a significant milestone for the company in ensuring the sustainability of the medicine supply chain and strengthening the company’s strategic position as a provider of quality generic drugs and a partner to the Government.

The receipt of these marketing authorization extensions serves as validation of Holi Pharma’s nationally tested product quality. With the renewed authorization status, Holi Pharma ensures that the company’s product pipeline remains secure and maintained, particularly in meeting regular market needs. This also affirms the company’s infrastructural readiness to continue supporting the National Health Insurance (JKN) program without administrative hurdles.

The step to secure marketing authorizations is also in line with the government’s major agenda in accelerating access to medicine. Bedjo Stefanus, Chief Operating Officer (COO) of PYFA, expressed his gratitude for the trust once again granted by the regulator to the company’s subsidiary. He emphasized that this success reflects the company’s dedication to strict quality standards.

“We are very grateful to have once again received this marketing authorization trust. PYFA will remain committed to providing the best service to the community and ensuring every product we distribute meets the highest standards of safety and efficacy. This also serves as a guarantee to our partners that the company’s operations are on track to support national health needs,” said Bedjo.

The certainty of these NIE renewals is a tangible manifestation of PYFA’s ongoing efforts to strengthen its business fundamentals. Moving forward, PYFA is committed to continuing its active role in maintaining the availability of essential medicines and establishing strategic collaborations with regulators to create a more resilient and trusted Indonesian healthcare ecosystem.